ArticleVeterinary world2025
Biomarker-based evaluation of aflatoxin B1 exposure in cattle.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Assessment of aflatoxin B1 (AFB1) exposure in cattle traditionally relies on feed analysis, which may not reflect chronic exposure or accurately indicate individual susceptibility. This study aimed to evaluate the utility of serum AFB1-albumin adducts and blood AFB1-DNA adducts as biomarkers for assessing individual chronic AFB1 exposure in cattle, irrespective of immediate feed contamination levels. Materials and Methods: Blood samples were collected from 53 crossbred cattle from farms, clinical veterinary cases, and slaughterhouses in Puducherry, India. Feed samples (n = 40) from farm and clinical cases were analyzed for aflatoxin contamination using two-dimensional thin-layer chromatography. AFB1 exposure was quantified by measuring serum AFB1-albumin adducts and blood AFB1-DNA adducts using an indirect enzyme-linked immunosorbent assay. In addition, a novel method was developed to synthesize the aflatoxin B1-formamidopyrimidine (AFB1-FAPy) adduct Results: AFB1 was detected in 50% of feed samples, with 70% of positive samples exceeding the maximum permissible limit of 20 μg/kg. Despite variable feed contamination, serum AFB1-albumin and blood AFB1-DNA adducts were consistently detected across all animal categories. Median AFB1-albumin adduct levels were similar among farm (0.730 pg/mg), clinical (0.670 pg/mg), and slaughterhouse (0.770 pg/mg) cattle (p = 0.731). Median AFB1-DNA adduct levels were highest in slaughterhouse cattle (18.33 pmol/μg DNA), followed by farm (14.76 pmol/μg DNA) and clinical cases (7.47 pmol/μg DNA), although differences were not statistically significant (p = 0.328). No significant correlation was observed between feed contamination levels and biomarker concentrations, highlighting the chronic nature of AFB1 exposure. Conclusion: The consistent detection of AFB1-albumin and AFB1-DNA adducts in cattle, irrespective of detectable aflatoxin levels in feed, underscores the limitations of traditional feed analysis for monitoring chronic exposure. The novel synthesis and robust detection of AFB1-FAPy DNA adducts further enhance the reliability of these biomarkers. These biomarkers are minimally invasive, sensitive, and valuable for chronic aflatoxin exposure assessment, aiding proactive management strategies to safeguard animal health and public food safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.